Other signatures were also identified in this analysis that implicates previously unreported processes in Vκ*MYC disease biology including signatures related to knockdown of the tumour suppressor TCF21, KRAS mutations, and constitutive activation of the RHOA oncogene. This evidence concerns the gene TCF21 and neoplasm.